News
NICE Terminates Tecentriq Appraisal
NICE (UK): NICE is unable to make a recommendation about the use in the NHS of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults
This is because Roche Products has confirmed that it does not intend to make an evidence submission for the appraisal. Roche Products considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this population.
Condition: Non Small Cell Lung Cancer
Type: drug